We are live on
!
Find out more
Alphabet Inc Portfolio holdings
AUM
$99.1B
Turnover
13.79%
1-Year Est. Return
124.46%
This Fund
S&P 500
This Quarter
Est. Return
+32.02%
1 Year Est. Return
+124.46%
3 Year Est. Return
+326.82%
5 Year Est. Return
+231.24%
10 Year Est. Return
+1,201.66%
AUM
$2.58B
AUM Growth
+$171M
(+7.1%)
Cap. Flow
-$313M
Cap. Flow
% of AUM
-12.12%
Top 10 Holdings %
Top 10 Hldgs %
92.81%
Holding
37
New
–
Increased
–
Reduced
3
Closed
8
Avg Time Held
3.9
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
2.1
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MTSR
Metsera Inc
MTSR
|
+$198M |
| 2 |
Revolution Medicines
RVMD
|
+$51.7M |
| 3 |
Maze Therapeutics
MAZE
|
+$35.2M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$9.69M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$8.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 49.93% |
| 2 | Healthcare | 25.65% |
| 3 | Industrials | 24.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
AST SpaceMobile
ASTS
$12.5B
| $650M | 25.18% |
8,943,486
| – | – |
2025 Q1
3 quarters
|
|
2
Planet Labs
PL
$5.07B
| $630M | 24.42% |
31,942,641
| – | – |
2021 Q4
16 quarters
|
|
|
3
Revolution Medicines
RVMD
$41.6B
| $266M | 10.33% |
3,345,102
-788,175
| -19% | -$51.7M |
2023 Q4
8 quarters
|
|
4
Arm
ARM
$253B
| $214M | 8.31% |
1,960,784
| – | – |
2023 Q3
9 quarters
|
|
5
Freshworks
FRSH
$3.74B
| $199M | 7.7% |
16,206,643
| – | – |
2021 Q4
16 quarters
|
|
6
UiPath
PATH
$6.95B
| $115M | 4.47% |
7,034,337
| – | – |
2021 Q2
18 quarters
|
|
7
GitLab
GTLB
$8.93B
| $102M | 3.96% |
2,724,712
| – | – |
2022 Q2
14 quarters
|
|
8
Tempus AI
TEM
$12.7B
| $91.6M | 3.55% |
1,551,102
| – | – |
2024 Q2
6 quarters
|
|
9
DexCom
DXCM
$32.7B
| $68.8M | 2.67% |
1,036,937
| – | – |
2018 Q4
28 quarters
|
|
|
10
Maze Therapeutics
MAZE
$1.52B
| $57.5M | 2.23% |
1,388,583
-1,023,888
| -42% | -$35.2M |
2025 Q1
3 quarters
|
|
11
Prime Medicine
PRME
$620M
| $57.5M | 2.23% |
16,562,498
| – | – |
2022 Q4
12 quarters
|
|
12
BridgeBio Oncology
BBOT
$236M
| $35.3M | 1.37% |
2,823,126
| – | – |
2025 Q3
1 quarter
|
|
13
Relay Therapeutics
RLAY
$3.82B
| $13.3M | 0.51% |
1,568,753
| – | – |
2020 Q3
21 quarters
|
|
14
Vera Therapeutics
VERA
$2.01B
| $12.2M | 0.47% |
241,264
| – | – |
2021 Q2
18 quarters
|
|
|
15
Monte Rosa Therapeutics
GLUE
$861M
| $11.7M | 0.45% |
744,948
-719,067
| -49% | -$9.69M |
2021 Q2
18 quarters
|
|
16
Sana Biotechnology
SANA
$730M
| $11.4M | 0.44% |
2,812,500
| – | – |
2021 Q1
19 quarters
|
|
17
Lyell Immunopharma
LYEL
$192M
| $9.03M | 0.35% |
293,256
| – | – |
2021 Q2
18 quarters
|
|
18
Beam Therapeutics
BEAM
$2.47B
| $8.91M | 0.35% |
321,604
| – | – |
2020 Q1
23 quarters
|
|
19
Figma
FIG
$12.1B
| $8.06M | 0.31% |
215,582
| – | – |
2025 Q3
1 quarter
|
|
20
Oscar Health
OSCR
$10.2B
| $6.93M | 0.27% |
481,988
| – | – |
2021 Q1
19 quarters
|
|
21
GeneDx Holdings
WGS
$2.1B
| $2.95M | 0.11% |
22,711
| – | – |
2024 Q3
5 quarters
|
|
22
DELISTED
Exact Sciences
EXAS
| $2.36M | 0.09% |
23,205
| – | – |
2021 Q3
17 quarters
|
|
23
Spero Therapeutics
SPRO
$65.8M
| $2.07M | 0.08% |
889,979
| – | – |
2017 Q4
32 quarters
|
|
24
Autolus Therapeutics
AUTL
$458M
| $1.39M | 0.05% |
698,262
| – | – |
2018 Q2
30 quarters
|
|
25
Hyperfine
HYPR
$83.4M
| $881K | 0.03% |
898,720
| – | – |
2021 Q4
16 quarters
|
|
Similar funds
Alphabet Inc's Q4 2025 Portfolio in Review
As of Q4 2025, Alphabet Inc held 37 positions worth $2.58B, up 7.1% from $2.41B the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Alphabet Inc withdrew a net $313M in Q4 2025, closing 8 positions and reducing 3 holdings. Its most notable exit was Metsera Inc, an estimated $198M position sold in full.
By sector, the portfolio is most concentrated in Technology at 50% of assets, up from 47% a quarter earlier, followed by Healthcare and Industrials.
- Alphabet Inc's biggest Q4 2025 reduction was Revolution Medicines, cutting an estimated $51.7M.
- Alphabet Inc fully exited Metsera Inc in Q4 2025, selling an estimated $198M.
- Alphabet Inc's ten largest holdings make up 93% of its $2.58B portfolio in Q4 2025.
- Alphabet Inc opened 0 new positions and closed 8 in Q4 2025.
- Alphabet Inc's portfolio value rose 7.1% quarter-over-quarter to $2.58B.
Based on Alphabet Inc's 13F filing for Q4 2025, filed 13 Feb 2026.